Sight Sciences Q2 revenue rises 20%, beats estimates
SGHT•Guidance increased for 2026
- Sight Sciences raises 2026 revenue guidance to $88 mln-$92 mln from $83 mln-$89 mln
- Company now sees 2026 Interventional Glaucoma revenue at $79 mln-$81 mln, up 4%-7%
- Company reduces 2026 adjusted operating expense guidance to $92 mln-$94 mln from $93 mln-$96 mln
Result drivers and analyst coverage
-
Dry eye segment growth - Interventional Dry Eye revenue rose sharply, driven by increased volumes and higher average selling prices
-
Glaucoma segment volumes - Interventional Glaucoma revenue increased, primarily due to higher volumes
-
Operating expense reduction - Total operating expenses fell 11% yr/yr, mainly due to lower personnel-related expenses and stock-based compensation
-
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
-
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
